See the DrugPatentWatch profile for cosentyx

Based on the information available, it is not possible to provide a definitive answer regarding the safety of live vaccines post Cosentyx (secukinumab) treatment. Cosentyx is a medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody that works by targeting a specific protein in the body (interleukin-17A) [1].

According to the Cosentyx prescribing information, "the use of live, attenuated vaccines during or following treatment with COSENTYX is not recommended" [1]. However, the document does not provide specific information on the safety of live vaccines post Cosentyx treatment.

DrugPatentWatch.com, a website that provides information on drug patents and pharmaceutical industry news, does not have any specific information on the safety of live vaccines post Cosentyx treatment [2].

Therefore, it is recommended to consult with a healthcare provider for personalized medical advice regarding the safety of live vaccines post Cosentyx treatment.

Sources:

* [1] Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) [prescribing information]. January 2023. Available at: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
* [2] DrugPatentWatch. Cosentyx (secukinumab) [patent information]. Available at: <https://www.drugpatentwatch.com/drugs/cosentyx>.